Compare Cisco Systems Inc (CSCO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cisco Systems Inc vs Recursion Pharmaceuticals Inc — how do they compare? Cisco Systems Inc trades at $112.37 (market cap $461.50B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B). The key difference: Cisco Systems Inc is far larger — about 259.3× Recursion Pharmaceuticals Inc's market cap, and Cisco Systems Inc pays a 1.43% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CSCO | RXRX | |
|---|---|---|
Market Cap | $461.50B | $1.78B |
Volume | 22,887,319 | — |
Sector | Technology | Health |
52-Week High | $130.00 | $6.79 |
52-Week Low | $66.20 | $2.84 |
Enterprise Value | $476.17B | $1.19B |
Dividend Yield | 1.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cisco Systems (CSCO) trades at $119.25, down 1.7% over 24 hours, with a bullish technical signal from moving averages and recent AI-driven news boosting sentiment. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.06 exceeding the $1.03 estimate. Financials show solid profitability with a 64.33% gross margin and $10.18B net income for 2025, though valuation ratios like P/E of 39.03 appear elevated. Analyst consensus is bullish with a $130.38 price target, supported by 38 buy ratings.
Outlook remains positive due to AI cybersecurity demand and partnerships, but risks include high debt levels and competitive pressures. The stock offers growth potential from tech infrastructure trends, yet investors should monitor execution on AI initiatives and macroeconomic headwinds that could impact networking spending.
RXRX trades at $3.30, down 7.3% today, with bearish technical signals from moving averages and oscillators. The clinical-stage biotech shows severe financial strain with a -851.51% net income margin and negative cash flow from operations of -$372M in 2025, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights AI-driven drug discovery potential but questions commercial viability.
Despite analyst consensus price target of $7.83 suggesting 137% upside, high cash burn and unproven business model pose substantial risk. Investment appeal hinges on successful drug development milestones, but current fundamentals indicate speculative positioning suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cisco Systems Inc
Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
